SCHEMBL16201410

SCHEMBL16201410

CCCN(C)Cc1c[nH]nc1-c1cccc(N(C)C)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 2/20 0.38
PRMT6 Q96LA8 3/20 0.36
PRMT8 Q9NR22 3/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
TP53 P04637 1/20 0.36
MAPT P10636 1/20 0.36
GFER P55789 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
HSD17B10 Q99714 1/20 0.36
LRRK2 Q5S007 1/20 0.35
PRMT3 O60678 2/20 0.34
CARM1 Q86X55 2/20 0.34
PRMT1 Q99873 2/20 0.34
AURKA O14965 1/20 0.34
MAP4K1 Q92918 1/20 0.32
NTRK1 P04629 1/20 0.32
FYN P06241 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16201239 0.89 PRMT6 (0.47) NOTUMPRMT6PRMT8NPC1RAB9A
SCHEMBL16201382 0.86 SMN1; SMN2 (0.41) PRMT6PRMT8KDM4EALDH1A1MAPT
SCHEMBL16201373 0.85 STK4 (0.44) PRMT6PRMT8NPC1RAB9AALDH1A1
SCHEMBL16201329 0.85 NPC1 (0.44) PRMT6PRMT8NPC1RAB9AKDM4E
SCHEMBL16201341 0.84 MOK (0.37) PRMT6PRMT8ALDH1A1PRMT3CARM1
SCHEMBL16201387 0.84 GAA (0.41) NOTUMNPC1RAB9AKDM4EALDH1A1
SCHEMBL16201334 0.82 LRRK2 (0.40) ALDH1A1HSD17B10LRRK2
SCHEMBL16201368 0.81 CARM1 (0.38) PRMT6PRMT8MAPTLRRK2PRMT3
SCHEMBL16201446 0.81 PRMT6 (0.42) PRMT6PRMT8PRMT3CARM1PRMT1
SCHEMBL16201455 0.81 KDM5A (0.38) PRMT6PRMT8NPC1RAB9APRMT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9776972-B2 Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof EPIZYME INC. (US) 2017-10-03 US disclosed
US-9346761-B2 Arginine methyltransferase inhibitors and uses thereof Epizyme, Inc. (US) 2016-05-24 US disclosed
US-20160137609-A1 PYRAZOLE DERIVATIVES AS ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2016-05-19 US disclosed
US-20140323537-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2014-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140323537-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF PRMT1, PRMT3, PRMT5 NOTUM 673/4885PRMT6 4/4885PRMT8 6/4885
US-20160137609-A1 PYRAZOLE DERIVATIVES AS ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF PRMT1, PRMT3, PRMT5 NOTUM 1329/4885PRMT6 5/4885PRMT8 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.